Anthem Biosciences IPO

Company Overview Incorporated in 2006, Anthem Biosciences Limited is a technology-focused and innovation-led Contract Research, Development, and Manufacturing Organisation (CRDMO). The company provides fully integrated services that span the entire drug development cycle from discovery to commercial manufacturing, serving a global clientele of emerging biotech startups and established pharmaceutical giants.

Anthem’s capabilities cover the manufacture of specialised fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, biosimilars, nutritional actives, and vitamin analogues. The company stands out in its ability to offer end-to-end solutions in both small molecules and biologics, using advanced technologies like RNAi, ADCs, and green chemistry practices.

Operational Highlights As of September 30, 2024, Anthem was actively engaged in:

• 170 Discovery Projects (284 synthesised molecules)

• 132 Early Phase Projects

• 16 Late Phase Projects (10 molecules)

• 13 Commercial Manufacturing Projects

In the six months ending September 30, 2024, the company was manufacturing APIs and intermediates for 10 commercial molecules, all of which have been supported by Anthem since their early discovery stages.

Anthem has a robust global presence with a customer base of over 550 (as of March 31, 2024) in its CRDMO and speciality ingredients businesses, spread across 44+ countries, including key markets like the United States, Europe, and Japan.

Key Strengths:

• Comprehensive drug development services across small molecules and biologics

• Advanced scientific capabilities in RNAi, ADCs, peptides, and fermentation technologies

• Focused support model for smaller biotech firms

• Long-standing relationships with global clients

• Strong leadership backed by skilled R&D talent

Key Risks:

• Risk of failure to innovate or improve existing technologies

• Delays in obtaining necessary regulatory approvals

• Under-utilisation of facilities and forecasting issues

• Pricing pressures impacting margins

• Data breaches and cyber security threats

• Seasonal variations in demand and cash flow

Anthem Biosciences IPO Details

• IPO Dates: 14th to 16th July 2025

• Price Band: ₹540 to ₹570 per share

• Lot Size: 26 Shares

• Total Issue Size: ₹3,395 crores (Offer for Sale)

• Retail Quota: 35%

• Grey Market Premium (GMP): ~18% (for information only)
  

Allotment Link

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.